-
公开(公告)号：US20200062730A1
公开(公告)日：2020-02-27
申请号：US16609805
申请日：2018-05-11
Inventor： Jong Yeon HWANG , Jae Du HA , Sung Yun CHO , Pil Ho KIM , Chang Soo YUN , Chi Hoon PARK , Chong Ock LEE , Sang Un CHOI , Joo Youn LEE , Sunjoo AHN
IPC: C07D401/04 , A61P35/00 , C07D401/14
Abstract: The present disclosure relates to a novel piperidine-2,6-dione derivative and a use thereof and, more specifically, to a piperidine-2,6-dione derivative compound having a structure of a thalidomide analog. A compound of chemical formula 1 according to the present disclosure specifically binds with CRBN protein, and is involved in functions thereof. Therefore, the compound of the present disclosure can be favorably used in the prevention or treatment of leprosy, chronic graft versus host disease, an inflammatory disease, or cancer, which are caused by actions of CRBN protein.
-
2.发明公开公开(公告)号：US20240285778A1
公开(公告)日：2024-08-29
申请号：US18573904
申请日：2022-06-24
Inventor： Pil Ho KIM , Sung Yun CHO , Jae Du HA , Chi Hoon PARK , Jong Yeon HWANG , Hyun Jin KIM , Song Hee LEE , Ye Seul LIM , Han Wool KIM , Sun Mi YOO , Beom Seon SUH , Ji Youn PARK , Je Ho RYU , Jung Min AHN , Hee Jung MOON , Ho Hyun LEE
CPC classification number: A61K47/55 , A61K47/545 , A61K47/60
Abstract: The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.
-
公开(公告)号：US20250082762A1
公开(公告)日：2025-03-13
申请号：US18949466
申请日：2024-11-15
Inventor： Pil Ho KIM , Sung Yun CHO , Jae Du HA , Chi Hoon PARK , Jong Yeon HWANG , Hyun Jin KIM , Song Hee LEE , Ye Seul LIM , Han Wool KIM , Sun Mi YOO , Beom Seon SUH , Ji Youn PARK , Je Ho RYU , Jung Min AHN , Hee Jung MOON , Ho Hyun LEE
Abstract: The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.
-
公开(公告)号：US20250073341A1
公开(公告)日：2025-03-06
申请号：US18949437
申请日：2024-11-15
Inventor： Pil Ho KIM , Sung Yun CHO , Jae Du HA , Chi Hoon PARK , Jong Yeon HWANG , Hyun Jin KIM , Song Hee LEE , Ye Seul LIM , Han Wool KIM , Sun Mi YOO , Beom Seon SUH , Ji Youn PARK , Je Ho RYU , Jung Min AHN , Hee Jung MOON , Ho Hyun LEE
Abstract: The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.
-
公开(公告)号：US20240252488A1
公开(公告)日：2024-08-01
申请号：US18246773
申请日：2021-09-27
Inventor： Jong Yeon HWANG , Hyunjun KIM , Hyowon MUN , Hyun Jin KIM , Jae Du HA , Sung Yun CHO , Chang Soo YUN , Pilho KIM , Jisoo LEE , Joon Gyo OH
IPC: A61K31/497 , A61K31/4439 , A61K31/444 , A61K47/54 , A61K47/55 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14
CPC classification number: A61K31/497 , A61K31/4439 , A61K31/444 , A61K47/545 , A61K47/55 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14
Abstract: The present disclosure provides a compound of a specific chemical structure binding to MLKL or having an MLKL inhibiting or degrading activity, or pharmaceutically acceptable salts thereof. The present disclosure provides a composition comprising such compound or pharmaceutically acceptable salts thereof. The present disclosure provides the pharmaceutical use of the compound according to the present invention, salts thereof, and a composition comprising same for treating or preventing MLKL-related diseases. The present disclosure also provides a method for treating or preventing MLKL-related diseases, comprising administering to a subject in need of treatment an effective amount of a compound according to the present invention, salts thereof, or a composition comprising same.
-
Patent Agency Ranking
公开(公告)号：US20220105188A1
公开(公告)日：2022-04-07
申请号：US17429321
申请日：2020-02-07
Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY , KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
Inventor： Jong Yeon HWANG , Jae Du HA , Sung Yun CHO , Pilho KIM , Chang Soo YUN , Hyun Jin KIM , Sung Goo PARK , Byoung Chul PARK , Jeong Hoon KIM , Sunhong KIM
Abstract: The present invention relates to a target protein degradation-inducing Degraducer, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases related to EED, EZH2, or PRC2 comprising same as an active ingredient. A novel compound represented by formula 1, according to the present invention is a Degraducer compound that induces degradation of a target protein, i.e., EED or PRC2, utilizing cereblon E3 ubiquitin ligase, VHL E3 ubiquitin ligase, MDM2 E3 ubiquitin ligase, and cIAP E3 ubiquitin ligase, wherein the compound has an aspect of remarkably achieving target protein degradation-inducing activity through a ubiquitin proteasome system (UPS), and therefore there is a useful effect in that it is possible to provide a pharmaceutical composition for preventing or treating diseases or conditions related to a target protein, and a functional health food composition for preventing or improving same, comprising said compound as an active ingredient.
-
公开(公告)号：US20180104242A1
公开(公告)日：2018-04-19
申请号：US15567224
申请日：2015-12-30
Inventor： Jong Yeon HWANG , Hyoung Rae KIM , Jae Du HA , Sung Yun CHO , Hee Jung JUNG , Pilho KIM , Chang Soo YUN , Chong Ock LEE , Chi Hoon PARK , Chong Hak CHAE , Sunjoo AHN
IPC: A61K31/506 , A61P35/00 , C07D239/48 , C07D239/30 , C07C13/48 , C07B43/04
CPC classification number: A61K31/506 , A23L33/10 , A61P35/00 , C07B43/04 , C07B2200/07 , C07C13/48 , C07D239/30 , C07D239/48
Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
-
8.发明公开公开(公告)号：US20240018123A1
公开(公告)日：2024-01-18
申请号：US18017997
申请日：2021-07-28
Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY , KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY , UBIX THERAPEUTICS, INC.
Inventor： Jong Yeon HWANG , Jae Du HA , Hyun Jin KIM , Sung Yun CHO , Pilho KIM , Chong Ock LEE , Jeong Hoon KIM , Byoung Chul PARK , Sung Goo PARK , Sunhong KIM , Yuri CHOI , Yaejin WOO , Song Hee LEE , Je Ho RYU , Jungmin AHN , Ji Youn PARK , Onnuri BAE , Hanwool KIM
IPC: C07D401/14 , C07D295/155 , C07D211/26
CPC classification number: C07D401/14 , C07D211/26 , C07D295/155
Abstract: The present disclosure provides a compound of a chemical structure having the ability of inhibiting or disintegrating an androgen receptor (AR), or a pharmaceutically acceptable salt of the compound. The present disclosure also provides a composition comprising such a compound or a pharmaceutically acceptable salt thereof. The present disclosure provides a pharmaceutical use of a compound according to the present disclosure, a salt thereof, and a composition comprising same for the treatment or prevention of AR-related diseases. The present disclosure also provides a method for treating or preventing AR-related diseases, comprising administering to a subject in need of treatment an effective amount of a compound according to the present disclosure, a salt thereof, or a composition comprising same.
-
公开(公告)号：US20200087286A1
公开(公告)日：2020-03-19
申请号：US16610327
申请日：2018-05-02
Inventor： Sung Yun CHO , Chang Hoon LEE , Yong Ki MIN , Jong Yeon HWANG
IPC: C07D403/14 , C07D239/48 , C07D403/04 , C07D413/14 , C07D405/04 , C07D409/14 , C07D417/14 , C07D405/14
Abstract: The present invention relates to a pyrimidine derivative compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a composition for preventing or treating cancer comprising the same as an active ingredient. The pyrimidine derivative compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof according to the present invention has an excellent selective inhibitory effect especially against TYRO 3 among TAM receptor inhibitory effects, and thus can be used as an excellent composition of preventing or treating cancer without adverse effects resulting from the inhibition of Axl and Mer.
-
10.发明申请公开(公告)号：US20170145007A1
公开(公告)日：2017-05-25
申请号：US15319151
申请日：2015-05-21
Inventor： Chang Soo YUN , Hyoung Rae KIM , Sung Yun CHO , Hee Jung JUNG , Kwangho LEE , Chong Hak CHAE , Chong Ock LEE , Chi Hoon PARK , Pilho KIM , Jong Yeon HWANG , Jae DU HA , Sun Joo AHN
IPC: C07D471/04 , C07D405/14 , C07D401/14 , C07D403/12 , C07D401/12
CPC classification number: C07D471/04 , A61K31/506 , C07D209/04 , C07D239/12 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14
Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.022 seconds)
